FREDERICK, Md., April 30 /PRNewswire/ -- Royer Animal Health, LLC, a wholly owned subsidiary of Royer Biomedical, Inc., has executed an exclusive distribution agreement with MWI Veterinary, Supply, Inc. (Nasdaq: MWIV) to market its lead animal health products: MATRIX III CISPLATIN BEADS and R-GEL ANTIBIOTIC WOUND DRESSING. These proprietary, timed-release products provide veterinary professionals with localized treatment options for cancer, infections, and general wound management.
By providing locally controlled delivery and increased drug concentration, Royer Animal Health therapies have proven to be highly effective, with no systemic side effects. These innovative products have only recently become available, they are currently being used in over 600 veterinary clinics and by 40 veterinary schools / teaching hospitals worldwide.
MATRIX III CISPLATIN BEADS have been clinically proven highly effective in the treatment of certain cancers with tumor rates of less than 10% reported. These fully-resorbable, [3 mm] Cisplatin Bead implants are indicated for use in the local control of equine sarcoids; clinical studies have also shown the effective use of Matrix III Cisplatin Beads in other tumor types including: melanoma, squamous cell, carcinoma and osteosarcoma. The product is safe, easy to use and manufactured under FDA -compliant conditions and represent a major breakthrough in cost-effective veterinary chemotherapy."
R-GEL ANTIBIOTIC WOUND DRESSING, is a timed-release antibiotic gel that solidifies in situ. It provides a sustained therapeutic dose of amikacin and clindamycin at the site of administration for a period of 7-9 days. The R-GEL matrix is biodegradable and fully resorbed in about 4 weeks. R-GEL has proven to be highly effective in the treatment of a wide range of small and large animal indications including: contaminated wounds, dental abscesses, deep lacerations, bite wounds, necrotic tissue, infected tendon sheaths, septic joints, post-operative orthopedic infections and hoof abscesses.
Supplied in a dual-syringe Kit for easy administration, R-GEL is available in both a 2ml and a 4 ml dose.
Dr. Gar Royer, President and CEO of Royer Animal Health, commented: "We are very pleased to be entering into this relationship with MWI, and believe that many new practitioners, as well as their patients and clients will benefit from the positive outcomes that will result by using our innovative products."
Royer Animal Health, LLC has developed novel superior products utilizing proprietary drug delivery technologies. Our mission is to provide veterinary professional with localized drug delivery products providing increased drug concentration to the targeted site versus systemic delivery, and consequently enhanced efficacy, without systemic side effects. Both Matrix III and R-Gel drug delivery matrices, are bio-resorbable, and have the ability to provide an effective, controlled release of drugs over a broad range of time spans. For more information about Royer Animal Health, please visit our website at www.RoyerAH.com.
MWI is a distributor of animal health products to veterinarians across the United States. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. They market these products to veterinarians in both the companion animal and production animal markets. For more information about MWI, please visit our website at www.mwivet.com.
For more information contact: Steve Kirschner at 301.696.2177
|SOURCE Royer Animal Health|
Copyright©2009 PR Newswire.
All rights reserved